Small Molecules
24 September 2019
Neurana Pharmaceuticals Announces Positive Topline Results from Phase 2 STAR Study of Tolperisone in Acute Muscle Spasms of the Back24 September 2019
AVEO Oncology and EUSA Pharma Announce Presentation of Final PFS Results from Phase 2 Portion of the TiNivo Study in Renal Cell Carcinoma24 September 2019
Cerevel Therapeutics Announces Positive Results from a Phase 2 Study of Tavapadon in Patients with Early-stage Parkinson’s Disease23 September 2019
Qtrilmet recommended for approval in EU by CHMP for the treatment of type-2 diabetes20 September 2019
Evrenzo® (roxadustat) Tablets Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients20 September 2019
Aerie Pharmaceuticals Receives Positive CHMP Opinion for Rhokiinsa® in the European Union19 September 2019
CinDome Pharma Announces Start of Phase 2 Trial of Deuterated Domperidone (CIN-102)19 September 2019
Spruce Biosciences Announces Positive Results from 12-week, Phase 2a Study of Tildacerfont in Adults with Congenital Adrenal Hyperplasia18 September 2019
STORM Therapeutics Presents Breakthrough Data Showing in Vivo Efficacy and Therapeutic Proof of Concept for Targeting RNA Modifying Enzymes18 September 2019
Immunic, Inc. Doses First Healthy Volunteer in its Phase 1 Clinical Program of IMU-935, a Potentially Best-in-Class RORgt Inverse Agonist18 September 2019
FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma17 September 2019
Vertical Pharmaceuticals, LLC, an Osmotica Company, Announces Submission of New Drug Application for RVL-120117 September 2019
DURECT Announces Positive Data from its Phase 2a Clinical Trial of DUR-928 in Alcoholic Hepatitis17 September 2019
Omeros Corporation Announces Positive Results from Phase 1 Study of its Lead PDE7 Inhibitor in Development for Addiction17 September 2019
Poxel Initiates Phase 1b Multiple Ascending Dose (MAD) Trial for NASH Drug Candidate, PXL06517 September 2019
Amplyx Pharmaceuticals Announces Positive Preliminary Data from Ongoing Fosmanogepix Phase 2 Study in Candidemia17 September 2019
AC Immune Receives Milestone Payment in Connection with Initiation of a Phase 2 Trial of Tau PET Tracer PI-262016 September 2019
Kura Oncology Doses First Patient in Phase 1 Clinical Trial of Menin-MLL Inhibitor KO-539 in Acute Myeloid Leukemia16 September 2019
Cytokinetics Announces Data From Phase 1 Study of CK-3773274 at the HFSA 23ʳᵈ Annual Scientific Meeting13 September 2019
Ritter Pharmaceuticals Reports Top-Line Results from its Liberatus Phase 3 Trial of RP-G28 for Lactose Intolerance13 September 2019
Eisai and Biogen to Discontinue Phase III Clinical Studies of Bace Inhibitor Elenbecestat in Early Alzheimer’s DiseaseNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports